For the Inventor, By the Inventor

Enter assignee name

Hazelwood, MO, United States of America

Ocera Therapeutics, Inc.

USPTO Granted Patents = 27

% Expired Patents = 25.9

CIPO Patents = 5

EPO Patents = 12

Forward Citations = 230

Loading Chart...

Loading Chart...

39 inventors (with patents filed for the assignee):

Keith Anderson (11 out of 16 patents)

Peter Manini (10 out of 26 patents)

Jim Behling (10 out of 11 patents)

4. Christine Henderson Dougan (10 out of 11 patents)

5. Stephen William Watt (10 out of 16 patents)

6. Attilia Figini (10 out of 11 patents)

7. Eric Marsault (8 out of 24 patents)

8. Kamel Benakli (6 out of 11 patents)

9. Mark L Peterson (5 out of 21 patents)

10. Carl St-Louis (5 out of 8 patents)

11. Hamid R Hoveyda (5 out of 51 patents)

12. Graeme Lovat Fraser (4 out of 38 patents)

13. Luc Ouellet (3 out of 13 patents)

14. Sophie Beauchemin (3 out of 9 patents)

15. Ruoxi Lan (2 out of 38 patents)

Core Competencies:

Immunoregulatory Cells

L-Ornithine Phenylacetate

Macrocyclic Compounds

Ghrelin Receptor Modulators

Drug Discovery

Irritable Bowel Syndrome

Muscle Loss Treatment

Portal Hypertension

Gastrointestinal Dysmotility

Combinatorial Synthesis

Phenylbutyrate

Adsorbent Carbon Microspheres

27 patents: Sort by Forward Citations

1. 12491248 - Method for generating immunoregulatory cells in a blood-derived sample (2025-12-09),

2. 11266620 - Treatment of portal hypertension and restoration of liver function using L-ornithine phenylacetate (2022-03-08),

3. 11219611 - Formulations of L-ornithine phenylacetate (2022-01-11),

4. 11161802 - L-ornithine phenyl acetate and methods of making thereof (2021-11-02),

5. 11066352 - Processes of making L-ornithine phenylacetate (2021-07-20),

6. 10835506 - Treatment and prevention of muscle loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate (2020-11-17),

7. 10550069 - L-ornithine phenyl acetate and methods of making thereof (2020-02-04),

8. 10258602 - Macrocyclic ghrelin receptor modulators and methods of using the same (2019-04-16),

9. 10173964 - L-ornithine phenyl acetate and methods of making thereof (2019-01-08),

10. 10040751 - Intermediates for macrocyclic compounds (2018-08-07),

11. 9949949 - Macrocyclic ghrelin receptor modulators and methods of using the same (2018-04-24),

12. 9604909 - L-ornithine phenyl acetate and methods of making thereof (2017-03-28),

13. 9493505 - Macrocyclic modulators of the ghrelin receptor (2016-11-15),

14. 9409945 - Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery (2016-08-09),

15. 9371297 - Macrocyclic ghrelin receptor modulators and methods of using the same (2016-06-21),

Company Overview

Ocera Therapeutics, Inc. is a biopharmaceutical company based in Hazelwood, Missouri, focused on developing innovative therapies for patients with liver diseases. The company specializes in advancing treatments that address unmet medical needs, particularly in the areas of hepatic encephalopathy and other liver-related conditions. Through its research and development efforts, Ocera aims to improve patient outcomes and enhance the quality of life for individuals affected by these serious health issues.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

27 Patents

#3 in Hazelwood, MO

#174 in Missouri

#12,410 in US

#23,984 in the World

Hazelwood, MO, United States of America

Ocera Therapeutics, Inc.

Forward Citations = 230

39 inventors:

Keith Anderson (11 out of 16 patents)

Peter Manini (10 out of 26 patents)

Jim Behling (10 out of 11 patents)

4. Christine Henderson Dougan (10 out of 11 patents)

5. Stephen William Watt (10 out of 16 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Ocera Therapeutics, Inc.. Retrieved from https://idiyas.com/company/ocera-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…